Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany. more
Time Frame | EVO | Sector | S&P500 |
---|---|---|---|
1-Week Return | 2.36% | -3.39% | 0.2% |
1-Month Return | -13.87% | -1.92% | 2.72% |
3-Month Return | 31.32% | -10.54% | 7.31% |
6-Month Return | 17.16% | -4.47% | 10.44% |
1-Year Return | -57.26% | 4.06% | 27.53% |
3-Year Return | -79.07% | 0.94% | 30.88% |
5-Year Return | -62.15% | 36.67% | 89.21% |
10-Year Return | 115.32% | 102.87% | 199.95% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 446.44M | 500.92M | 618.03M | 751.45M | 781.43M | [{"date":"2019-12-31","value":57.13,"profit":true},{"date":"2020-12-31","value":64.1,"profit":true},{"date":"2021-12-31","value":79.09,"profit":true},{"date":"2022-12-31","value":96.16,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 313.55M | 375.18M | 466.49M | 577.38M | 606.38M | [{"date":"2019-12-31","value":51.71,"profit":true},{"date":"2020-12-31","value":61.87,"profit":true},{"date":"2021-12-31","value":76.93,"profit":true},{"date":"2022-12-31","value":95.22,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 132.89M | 125.74M | 151.54M | 174.06M | 175.05M | [{"date":"2019-12-31","value":75.92,"profit":true},{"date":"2020-12-31","value":71.83,"profit":true},{"date":"2021-12-31","value":86.57,"profit":true},{"date":"2022-12-31","value":99.44,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | 29.77% | 25.10% | 24.52% | 23.16% | 22.40% | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":84.33,"profit":true},{"date":"2021-12-31","value":82.37,"profit":true},{"date":"2022-12-31","value":77.82,"profit":true},{"date":"2023-12-31","value":75.26,"profit":true}] |
Operating Expenses | 58.38M | 73.98M | 109.86M | 153.22M | 282.14M | [{"date":"2019-12-31","value":20.69,"profit":true},{"date":"2020-12-31","value":26.22,"profit":true},{"date":"2021-12-31","value":38.94,"profit":true},{"date":"2022-12-31","value":54.3,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | 62.59M | 48.52M | 27.32M | 12.49M | (107.09M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":77.52,"profit":true},{"date":"2021-12-31","value":43.65,"profit":true},{"date":"2022-12-31","value":19.96,"profit":true},{"date":"2023-12-31","value":-171.08,"profit":false}] |
Total Non-Operating Income/Expense | (11.26M) | (29.84M) | 189.00M | (179.62M) | 771.00K | [{"date":"2019-12-31","value":-5.96,"profit":false},{"date":"2020-12-31","value":-15.79,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-95.04,"profit":false},{"date":"2023-12-31","value":0.41,"profit":true}] |
Pre-Tax Income | 56.56M | 25.81M | 236.98M | (153.96M) | (103.84M) | [{"date":"2019-12-31","value":23.87,"profit":true},{"date":"2020-12-31","value":10.89,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-64.97,"profit":false},{"date":"2023-12-31","value":-43.82,"profit":false}] |
Income Taxes | 19.33M | 19.55M | 21.47M | 21.70M | (40.68M) | [{"date":"2019-12-31","value":89.1,"profit":true},{"date":"2020-12-31","value":90.12,"profit":true},{"date":"2021-12-31","value":98.95,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-187.48,"profit":false}] |
Income After Taxes | 37.23M | 6.25M | 215.51M | (175.66M) | (63.16M) | [{"date":"2019-12-31","value":17.27,"profit":true},{"date":"2020-12-31","value":2.9,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-81.51,"profit":false},{"date":"2023-12-31","value":-29.31,"profit":false}] |
Income From Continuous Operations | 37.23M | 6.25M | 215.51M | (175.66M) | (83.91M) | [{"date":"2019-12-31","value":17.27,"profit":true},{"date":"2020-12-31","value":2.9,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-81.51,"profit":false},{"date":"2023-12-31","value":-38.94,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | 38.16M | 6.28M | 215.51M | (175.66M) | (83.91M) | [{"date":"2019-12-31","value":17.7,"profit":true},{"date":"2020-12-31","value":2.91,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-81.51,"profit":false},{"date":"2023-12-31","value":-38.94,"profit":false}] |
EPS (Diluted) | 1.06 | 0.09 | 3.42 | (0.58) | (0.29) | [{"date":"2019-12-31","value":31,"profit":true},{"date":"2020-12-31","value":2.57,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-16.86,"profit":false},{"date":"2023-12-31","value":-8.47,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
EVO | |
---|---|
Cash Ratio | 1.13 |
Current Ratio | 2.09 |
Quick Ratio | 1.99 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
EVO | |
---|---|
ROA (LTM) | -1.77% |
ROE (LTM) | -16.25% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
EVO | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.51 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.49 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
EVO | |
---|---|
Trailing PE | NM |
Forward PE | 59.88 |
P/S (TTM) | 2.13 |
P/B | 1.63 |
Price/FCF | 119 |
EV/R | 2.13 |
EV/Ebitda | NM |
Evotec SE ADR (EVO) share price today is $4.5
Yes, Indians can buy shares of Evotec SE ADR (EVO) on Vested. To buy Evotec SE ADR from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in EVO stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Evotec SE ADR (EVO) via the Vested app. You can start investing in Evotec SE ADR (EVO) with a minimum investment of $1.
You can invest in shares of Evotec SE ADR (EVO) via Vested in three simple steps:
The 52-week high price of Evotec SE ADR (EVO) is $12. The 52-week low price of Evotec SE ADR (EVO) is $2.85.
The price-to-earnings (P/E) ratio of Evotec SE ADR (EVO) is
The price-to-book (P/B) ratio of Evotec SE ADR (EVO) is 1.63
The dividend yield of Evotec SE ADR (EVO) is 0.00%
The market capitalization of Evotec SE ADR (EVO) is $1.70B
The stock symbol (or ticker) of Evotec SE ADR is EVO